APP and neoplasm: High-risk NB represents a significant therapeutic challenge due to its immunologically “cold” TME, characterized by limited immune cell infiltration [41,42], tumor heterogeneity [41], low mutational burden, and the reduced expression of MHC class I molecules and antigen processing and presentation (APP) pathway components, which limit tumor antigen recognition by T cells [2,43,44,45,46].